Professional
Added to YB: 2026-09-17
Pitch date: 2026-06-30
GH [bullish]
Guardant Health, Inc.
Author Info
No bio for this author
Company Info
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Market Cap
$22.5B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-58.46
P/E
-47.90
EV/Sales
19.58
Sector
Health Care Providers and Services
Category
growth
Aristotle Core Equity Fund Portfolio Holding: Guardant Health, Inc.
GH (hold): Guardant Health contributed to second-quarter performance as several catalysts played out: FDA approval of an updated Guardant360 liquid-biopsy test, American Cancer Society inclusion of Shield for colorectal-cancer screening, and stronger-than-expected first-quarter earnings driven by volume growth and coverage expansion.
Read full article (1 min)